Vaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trial

Vaxxinity Inc VAXX unveiled results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson's disease (PD).

UB-312 is a synthetic peptide vaccine targeting aggregated forms of aSyn, which plays a central role in PD development and progression.

UB-312 was well-tolerated and induced anti-alpha-synuclein (aSyn) antibody responses in participants with early PD, meeting the trial's primary objectives.

92% of patients (12 out of 13) who completed dosing with UB-312 developed anti-aSyn antibodies.

The results demonstrate important features for immunotherapy against PD and represent a proof-of-principle for Vaxxinity's platform in chronic disease.

UB-312 was well-tolerated, and antibodies were detectable in cerebrospinal fluid.

UB-312 safely broke immune tolerance, induced antibodies against toxic forms of alpha-synuclein, and showed potential target engagement in the periphery and crossing the blood-brain barrier.

The trial was not designed to measure differences in PD progression between UB-312 and placebo groups.

The Michael J. Fox Foundation is funding a collaborative project to evaluate the potential of UB-312 further and characterize the produced anti-aSyn antibodies.

Price Action: VAXX shares are down 2.38% at $2.05 on the last check Thursday.